222 related articles for article (PubMed ID: 33110170)
1. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
2. Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.
Igase M; Inanaga S; Nishibori S; Itamoto K; Sunahara H; Nemoto Y; Tani K; Horikirizono H; Nakaichi M; Baba K; Kambayashi S; Okuda M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
J Vet Sci; 2024 Jan; 25(1):e15. PubMed ID: 38311328
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
[TBL] [Abstract][Full Text] [Related]
4. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract][Full Text] [Related]
5. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract][Full Text] [Related]
6. A combination of electrochemotherapy, gene electrotransfer of plasmid encoding canine IL-12 and cytoreductive surgery in the treatment of canine oral malignant melanoma.
Milevoj N; Tratar UL; Nemec A; Brožič A; Žnidar K; Serša G; Čemažar M; Tozon N
Res Vet Sci; 2019 Feb; 122():40-49. PubMed ID: 30453179
[TBL] [Abstract][Full Text] [Related]
7. Use of the melanoma vaccine in 38 dogs: The South African experience.
McLean JL; Lobetti RG
J S Afr Vet Assoc; 2015 Apr; 86(1):1246. PubMed ID: 26016668
[TBL] [Abstract][Full Text] [Related]
8. PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems.
Muscatello LV; Gobbo F; Avallone G; Innao M; Benazzi C; D'Annunzio G; Romaniello D; Orioles M; Lauriola M; Sarli G
Vet Pathol; 2024 May; 61(3):393-401. PubMed ID: 37920996
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma.
Kamoto S; Shinada M; Kato D; Yoshimoto S; Ikeda N; Tsuboi M; Yoshitake R; Eto S; Hashimoto Y; Takahashi Y; Chambers J; Uchida K; Kaneko MK; Fujita N; Nishimura R; Kato Y; Nakagawa T
Cells; 2020 Nov; 9(11):. PubMed ID: 33238582
[TBL] [Abstract][Full Text] [Related]
10. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.
Thamm DH; Kurzman ID; Macewen EG; Feinmehl R; Towell TL; Longhofer SL; Johnson CM; Geoly FJ; Stinchcomb DT
Cancer Immunol Immunother; 2003 Aug; 52(8):473-80. PubMed ID: 12768328
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy.
Tarone L; Barutello G; Iussich S; Giacobino D; Quaglino E; Buracco P; Cavallo F; Riccardo F
Cancer Immunol Immunother; 2019 Nov; 68(11):1839-1853. PubMed ID: 31222484
[TBL] [Abstract][Full Text] [Related]
12. Limited Clinical Efficacy with Potential Adverse Events in a Pilot Study of Autologous Adoptive Cell Therapy in Canine Oral Malignant Melanoma.
Xia YY; Chi KH; Liao AT; Lee JJ
Vet Sci; 2024 Mar; 11(4):. PubMed ID: 38668417
[TBL] [Abstract][Full Text] [Related]
13. The human and animals' malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans.
Pinto C; Aluai-Cunha C; Santos A
Melanoma Res; 2023 Apr; 33(2):87-103. PubMed ID: 36662668
[TBL] [Abstract][Full Text] [Related]
14. Developing a translational murine-to-canine pathway for an IL-2/agonist anti-CD40 antibody cancer immunotherapy.
Proksch SF; Matthysen CP; Jardine JE; Wyatt KM; Finlay JR; Nelson DJ
Vet Comp Oncol; 2022 Sep; 20(3):602-612. PubMed ID: 35315197
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.
Zuleger CL; Kang C; Ranheim EA; Kurzman ID; Macklin MD; Newton MA; Wolchok JD; Vail DM; Eriksson E; Albertini MR
Vet Med Sci; 2017 Aug; 3(3):134-145. PubMed ID: 29067210
[TBL] [Abstract][Full Text] [Related]
16. Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology.
London CA; Gardner H; Zhao S; Knapp DW; Utturkar SM; Duval DL; Chambers MR; Ostrander E; Trent JM; Kuffel G
Vet Comp Oncol; 2023 Dec; 21(4):565-577. PubMed ID: 37778398
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison of canine and human immune responses using transcriptomic and functional analyses.
Chow L; Wheat W; Ramirez D; Impastato R; Dow S
Sci Rep; 2024 Jan; 14(1):2207. PubMed ID: 38272935
[TBL] [Abstract][Full Text] [Related]
18. Cancer Immunotherapy.
Bergman PJ
Vet Clin North Am Small Anim Pract; 2024 May; 54(3):441-468. PubMed ID: 38158304
[TBL] [Abstract][Full Text] [Related]
19. Current Status of Canine Melanoma Diagnosis and Therapy: Report From a Colloquium on Canine Melanoma Organized by ABROVET (Brazilian Association of Veterinary Oncology).
Fonseca-Alves CE; Ferreira Ê; de Oliveira Massoco C; Strauss BE; Fávaro WJ; Durán N; Oyafuso da Cruz N; Dos Santos Cunha SC; Castro JLC; Rangel MMM; Brunner CHM; Tellado M; Dos Anjos DS; Fernandes SC; Barbosa de Nardi A; Biondi LR; Dagli MLZ
Front Vet Sci; 2021; 8():707025. PubMed ID: 34485435
[No Abstract] [Full Text] [Related]
20. Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
Farrell M; Adams R; von Pfeil DJF
Vet J; 2024 Apr; 305():106104. PubMed ID: 38580157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
